Predictors of mortality in hospitalised patients with COVID-19: a 1-year case-control study.

BACKGROUND: A paucity of predictive models assessing risk factors for COVID-19 mortality that extend beyond age and gender in Latino population is evident in the current academic literature. OBJECTIVES: To determine the associated factors with mortality, in addition to age and sex during the first year of the pandemic. DESIGN: A case-control study with retrospective revision of clinical and paraclinical variables by systematic revision of clinical records was conducted. Multiple imputations by chained equation were implemented to account for missing variables. Classification and regression trees (CART) were estimated to evaluate the interaction of associated factors on admission and their role in predicting mortality during hospitalisation. No intervention was performed. SETTING: High-complexity centre above 2640 m above sea level (masl) in Colombia. PARTICIPANTS: A population sample of 564 patients admitted to the hospital with confirmed COVID-19 by PCR. Deceased patients (n=282) and a control group (n=282), matched by age, sex and month of admission, were included. MAIN OUTCOME MEASURE: Mortality during hospitalisation. MAIN RESULTS: After the imputation of datasets, CART analysis estimated 11 clinical profiles based on respiratory distress, haemoglobin, lactate dehydrogenase, partial pressure of oxygen to inspired partial pressure of oxygen ratio, chronic kidney disease, ferritin, creatinine and leucocytes on admission. The accuracy model for prediction was 80.4% (95% CI 71.8% to 87.3%), with an area under the curve of 78.8% (95% CI 69.63% to 87.93%). CONCLUSIONS: This study discloses new interactions between clinical and paraclinical features beyond age and sex influencing mortality in COVID-19 patients. Furthermore, the predictive model could offer new clues for the personalised management of this condition in clinical settings.

Phenomenon of tumor flare with talquetamab in a patient with extramedullary myeloma.

Not available.

[Fusarium meningoencephalitis in the late puerperium: A case report]. / Meningoencefalitis por Fusarium en puerperio tardío: reporte de caso.

Background: Fusarium infection in the central nervous system is a rare pathology generally reported in patients with hematological malignancies. Clincal case: A patient with Fusarium meningoencephalitis during the late postpartum period is presented. The patient's main symptom was holocranial headache with poor response to analgesics, adding dysarthria and blurred vision. Initially, it was classified as aseptic meningitis due to the absence of bacterial isolation, however, 8 weeks after the onset of the symptoms, Fusarium development was obtained in cerebrospinal fluid cultures. Targeted treatment with liposomal amphotericin and voriconazole was established, with partial improvement at first; however, at 16 weeks from the onset of the clinical picture, the patient presented sudden deterioration of alertness, an ischemic area was found in the occipital lobe by imaging study, which quickly led the patient to a fatal outcome. Conclusion: Despite the fact that in recent years Fusarium spp infection has been detected more frequently in the population, the treatment is still not well established, making management of the Central Nervous System a challenge.

Introducción: la infección por Fusarium en el sistema nervioso central es una patología rara, reportada generalmente en pacientes con neoplasias hematológicas. Caso clínico: se presenta una paciente con meningoencefalitis por Fusarium durante el periodo de puerperio tardío. El síntoma principal de la paciente fue cefalea holocraneana con baja respuesta a analgésicos, agregándose disartria y visión borrosa. De manera inicial, se catalogó como meningitis aséptica por ausencia de aislamiento bacteriano, no obstante, a las 8 semanas posterior al inicio del cuadro se obtuvo desarrollo de Fusarium en los cultivos de líquido cefalorraquídeo. Se estableció tratamiento dirigido con anfotericina liposomal y voriconazol, con mejoría parcial en un inicio; sin embargo, la paciente a las 16 semanas desde el inicio del cuadro clínico presentó deterioro súbito del estado de alerta, se evidenció zona isquémica en el lóbulo occipital por estudio de imagen, lo que rápidamente llevó a la paciente a un desenlace fatal. Conclusión: a pesar de que en los últimos años la infección por Fusarium spp se ha detectado con mayor frecuencia en la población, el tratamiento aún no se encuentra bien establecido ocasionando que sea un reto el manejo en Sistema Nervioso Central.

Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review.

Autoimmunity linked to COVID-19 immunization has been recorded throughout the pandemic. Herein we present six new patients who experienced relapses of previous autoimmune disease (AD) or developed a new autoimmune or autoinflammatory condition following vaccination. In addition, we documented additional cases through a systematic review of the literature up to August 1st, 2022, in which 464 studies (928 cases) were included. The majority of patients (53.6%) were women, with a median age of 48 years (IQR: 34 to 66). The median period between immunization and the start of symptoms was eight days (IQR: 3 to 14). New-onset conditions were observed in 81.5% (n: 756) of the cases. The most common diseases associated with new-onset events following vaccination were immune thrombocytopenia, myocarditis, and Guillain-Barré syndrome. In contrast, immune thrombocytopenia, psoriasis, IgA nephropathy, and systemic lupus erythematosus were the most common illnesses associated with relapsing episodes (18.5%, n: 172). The first dosage was linked with new-onset events (69.8% vs. 59.3%, P = 0.0100), whereas the second dose was related to relapsing disease (29.5% vs. 59.3%, P = 0.0159). New-onset conditions and relapsing diseases were more common in women (51.5% and 62.9%, respectively; P = 0.0081). The groups were evenly balanced in age. No deaths were recorded after the disease relapsed, while 4.7% of patients with new-onset conditions died (P = 0.0013). In conclusion, there may be an association between COVID-19 vaccination and autoimmune and inflammatory diseases. Some ADs seem to be more common than others. Vaccines and SARS-CoV-2 may induce autoimmunity through similar mechanisms. Large, well-controlled studies are warranted to validate this relationship and assess additional variables such as genetic and other environmental factors.

Is post-COVID syndrome an autoimmune disease?

INTRODUCTION: Post-COVID syndrome (PCS) is recognized as a new entity in the context of SARS-CoV-2 infection. Though its pathogenesis is not completely understood, persistent inflammation from acute illness and the development of autoimmunity play a critical role in its development. AREAS COVERED: The mechanisms involved in the emergence of PCS, their similarities with post-viral and post-care syndromes, its inclusion in the spectrum of autoimmunity and possible targets for its treatment. EXPERT OPINION: An autoimmune phenomenon plays a major role in most causative theories explaining PCS. There is a need for both PCS definition and classification criteria (including severity scores). Longitudinal and controlled studies are necessary to better understand this new entity, and to find what additional factors participate into its development. With the high prevalence of COVID-19 cases worldwide, together with the current evidence on latent autoimmunity in PCS, we may observe an increase of autoimmune diseases (ADs) in the coming years. Vaccination's effect on the development of PCS and ADs will also receive attention in the future. Health and social care services need to develop a new framework to deal with PCS.

Polymyalgia rheumatica: A case series from Colombia and analysis of Latin America.

OBJECTIVE: Polymyalgia rheumatica (PMR) is the most common inflammatory disease in patients over 50 years. Information about the disease in Latin America (LATAM) is scarce. We aimed to evaluate a group of Colombian patients with PMR and to conduct a systematic review of PMR in LATAM. METHODS: A multicentric retrospective study was performed. Medical records of 256 PMR patients were evaluated. Patients were divided into two groups, those fulfilling the 2012 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for PMR and those who did not (i.e., clinical diagnosis). A systematic literature review and meta regression was performed comparing Colombian vs LATAM patients. RESULTS: From 256 patients, 145 (56.6%) fulfilled the 2012 EULAR/ACR criteria, and 111 (43.3%) were classified by clinical diagnosis. Inflammatory bilateral shoulder pain, pelvic girdle aching, morning stiffness >45 min, elevated erythrocyte sedimentation rate (ESR), and C-reactive protein (CPR), and Methotrexate (MTX) prescription were more common in the 2012 EULAR/ACR group. None of the included patients presented overt polyautoimmunity (PolyA), whereas up to 24% exhibited latent PolyA. In addition, these patients showed high frequency of malignancy (7.59%). In the meta regression analysis, Colombian patients exhibited lower ESR levels, and were less likely to develop giant cell arteritis (GCA) as compared to the rest of LATAM data. CONCLUSION: Patients with PMR in LATAM exhibit similar phenotypes from other cohorts worldwide. Malignancy, GCA and latent PolyA should be considered in the routine clinical follow-up of patients with PMR.

Association between Candida biofilm-forming bloodstream isolates and the clinical evolution in patients with candidemia: An observational nine-year single center study in Mexico / Asociación entre aislamientos sanguíneos de Candida formadores de biopelícula y la evolución clínica en pacientes con candidemia: un estudio observacional monocéntrico de nueve años en México

Background. Candidemia is one of the most common nosocomial infections globally and it is associated with considerable excess mortality and costs. Abreast, biofilm-forming strains are associated with even higher mortality rates and poor prognosis for the patient. Aims. To evaluate a possible association between the biofilm-forming capability of Candida bloodstream isolates and the clinical evolution in patients with candidemia. Methods. An observational, retrospective study was conducted at a tertiary care university hospital during 9 years (2006-2015). The biofilm quantitation of the Candida bloodstream isolates was determined by crystal violet staining and XTT reduction assay. Results. A total of 218 cases of candidemia had been diagnosed and 89 isolates were obtained. The mortality rate was 36% and the main risk factors were antibiotic exposure and the use of catheters. Candida tropicalis (52.8%) was the most frequent species, followed by Candida albicans (30.4%), Candida parapsilosis sensu stricto (10.1%), Candida orthopsilosis (3.4%), Candida krusei (2.2%) and Candida glabrata sensu stricto (1.1%). All the strains were biofilm producers, which is an important contribution to the patient's mortality. C. tropicalis showed the highest production of biomass biofilm, whereas C. glabrata exhibited the highest metabolic activity. Conclusions. This study contributes to expand the knowledge about the local epidemiology of candidemia and highlights the impact of Candida biofilm on patient's outcome (AU)

Antecedentes. La candidemia es una de las infecciones nosocomiales más frecuentes globalmente y se encuentra asociada con una elevada mortalidad y coste económico. Las cepas productoras de biopelícula se asocian con elevadas tasas de mortalidad y mal pronóstico para el paciente. Objetivos. Evaluar una posible asociación entre la capacidad de formación de biopelícula de aislamientos sanguíneos de Candida y la evolución clínica de pacientes con candidemia. Métodos. Durante 9 años (2006-2015) se ha llevado a cabo un estudio observacional y retrospectivo en un hospital universitario de tercer nivel de atención. La cuantificación de biopelícula de los aislamientos sanguíneos de Candida se determinó por tinción con cristal violeta y ensayo de reducción de XTT. Resultados. Se diagnosticó un total de 218 casos de candidemia y se obtuvieron 89 aislamientos. La tasa de mortalidad fue del 36% y los principales factores de riesgo fueron la exposición a antibióticos y el uso de catéteres. Candida tropicalis (52,8%) fue la especie más frecuente, seguida por Candida albicans (30,4%), Candida parapsilosis sensu stricto (10,1%), Candida orthopsilosis (3,4%), Candida krusei (2,2%) y Candida glabrata sensu stricto (1,1%). Todas las cepas produjeron biopelícula, una contribución importante a la mortalidad de los pacientes. C. tropicalis mostró la producción más alta de biomasa de biopelícula, mientras que C. glabrata exhibió la actividad metabólica más alta. onclusiones. Este estudio contribuye a expandir el conocimiento de la epidemiología local de la candidemia y resalta el impacto de las biopelículas de Candida en el pronóstico del paciente (AU)

Association between Candida biofilm-forming bloodstream isolates and the clinical evolution in patients with candidemia: An observational nine-year single center study in Mexico.

BACKGROUND: Candidemia is one of the most common nosocomial infections globally and it is associated with considerable excess mortality and costs. Abreast, biofilm-forming strains are associated with even higher mortality rates and poor prognosis for the patient. AIMS: To evaluate a possible association between the biofilm-forming capability of Candida bloodstream isolates and the clinical evolution in patients with candidemia. METHODS: An observational, retrospective study was conducted at a tertiary care university hospital during 9 years (2006-2015). The biofilm quantitation of the Candida bloodstream isolates was determined by crystal violet staining and XTT reduction assay. RESULTS: A total of 218 cases of candidemia had been diagnosed and 89 isolates were obtained. The mortality rate was 36% and the main risk factors were antibiotic exposure and the use of catheters. Candida tropicalis (52.8%) was the most frequent species, followed by Candida albicans (30.4%), Candida parapsilosis sensu stricto (10.1%), Candida orthopsilosis (3.4%), Candida krusei (2.2%) and Candida glabrata sensu stricto (1.1%). All the strains were biofilm producers, which is an important contribution to the patient's mortality. C. tropicalis showed the highest production of biomass biofilm, whereas C. glabrata exhibited the highest metabolic activity. CONCLUSIONS: This study contributes to expand the knowledge about the local epidemiology of candidemia and highlights the impact of Candida biofilm on patient's outcome.

[Metoclopramide as a risk factor for postprandial hyperglycemia in type 2 diabetes]. / Metoclopramida, factor de riesgo para hiperglucemia postprandial en diabetes tipo 2.

UNLABELLED: Diabetes mellitus is a pathology that has widely spread througout the world in the past decades. Postprandial hyperglycemia plays an important role in the progress of the disease due to the fact that increases the risk for cardiovascular events. This study's aim was to determine if the use of intravenous metoclopramide in patients with Diabetes Mellitus increases the postprandial glycemia. MATERIAL AND METHODS: A cohort of patients hospitalized with type 2 diabetes mellitus. Patients were classified as exposed (metoclopramide 10 mg IV) and not exposed, and glycemia preprandial and postprandial at 30, 60 and 120 minutes was measured. RESULTS: There were 80 patients in each group, and in both groups the general characteristics were homogeneous. The postprandial glycemia in the exposed group was higher at 30, 60, 90 and 120 minutes, being only statistically significant at 120 minutes postprandial (p = < 0,001). CONCLUSIONS: In conclusion, the use of intravenous metoclopramide is a risk factor to develop postprandial hyperglycemia in diabetic patients.

Metoclopramida, factor de riesgo para hiperglucemia postprandial en diabetes tipo 2 / Metoclopramide as a risk factor for postprandial hyperglycemia in type 2 diabetes

La diabetes mellitus (DM) es una patología que ha crecido ampliamente a nivel mundial en las ultimas décadas. La hiperglucemia postprandial (HP) ha tomado importancia en los últimos años, ya que se ha visto se relaciona de manera directa con un aumento en el riesgo de eventos cardiovasculares. A la fecha, no se ha determinado la asociación entre el empleo de metoclopramida y los niveles de glucemia postprandial. Material y métodos: Se realizó un estudio de tipo cohorte, con objeto de determinar si la metoclopramida es factor de riesgo para hiperglucemia postprandial. Se incluyeron pacientes diabéticos tipo 2, se catalogó a los pacientes en expuestos, aquellos manejados con metoclopramida preprandial 10 mg intravenosa (IV) y no expuestos, se determinó glucemia preprandial y 30, 60, 90 y 120 minutos postprandiales. Resultados: 80 pacientes por grupo se incluyeron siendo sus características basales similares. Las glucemia postprandial fue más elevada en aquellos tratados con metoclopramida que sin esta (p = < 0,001)). Conclusiones: La metoclopramida IV es un factor de riesgo para hiperglucemia postprandial en pacientes con diabetes mellitus tipo 2 (AU)

Diabetes mellitus is a pathology that has widely spread througout the world in the past decades. Postprandial hyperglycemia plays an important role in the progress of the disease due to the fact that increases the risk for cardiovascular events. This study's aim was to determine if the use of intravenous metoclopramide in patients with Diabetes Mellitus increases the postprandial glycemia. Material and methods: A cohort of patients hospitalized with type 2 diabetes mellitus. Patients were classified as exposed (metoclopramide 10 mg IV) and not exposed, and glycemia preprandial and postprandial at 30, 60 and 120 minutes was measured. Results: There were 80 patients in each group, and in both groups the general characteristics were homogeneous. The postprandial glycemia in the exposed group was higher at 30, 60, 90 and 120 minutes, being only statistically significant at 120 minutes postprandial (p = < 0,001). Conclusions: In conclusion, the use of intravenous metoclopramide is a risk factor to develop postprandial hyperglycemia in diabetic patients (AU)